Chirality 1993-01-01

The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein.

S A Doggrell

Index: Chirality 5 , 8-14, (1993)

Full Text: HTML

Abstract

The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol alone on the rat left atria and portal vein and on the respective beta 1- and beta 2-adrenoceptor-mediated responses to isoprenaline have been determined. (+/-)-Atenolol at 10(-6) M had no effect whereas high concentrations of (+/-)- and (-)-sotalol, 10(-5)-10(-4) M, and (+/-)-, and (-)-amosulalol depressed the response of the rat left atria to cardiac stimulation which indicates membrane stabilizing activity. None of the drugs tested had any effect alone on the rat portal vein. The order of potency as antagonists was (+/-)-amosulalol > (+/-)-atenolol > (+/-)-sotalol at beta 1-adrenoceptors and (+/-)-amosulalol > (+/-)-sotalol > (+/-)-atenolol at beta 2-adrenoceptors. (+/-)-Atenolol and (+/-)-amosulalol are beta 1-selective whereas (+/-)-sotalol is beta 2-selective. For each of the racemic beta-blockers, the beta 1- and beta 2-adrenoceptor blocking activity was predominantly due to the (-)-enantiomer.


Related Compounds

  • Sotalol hydrochlor...
  • esatenolol
  • Atenolol

Related Articles:

A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.

2010-12-01

[Assay Drug Dev. Technol. 8 , 714-26, (2010)]

Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women.

2013-12-01

[Heart 99(23) , 1755-60, (2013)]

Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease.

2015-02-01

[Am. J. Cardiol. 115(3) , 316-22, (2015)]

In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements.

2012-01-01

[Cell Physiol. Biochem. 29(5-6) , 819-32, (2012)]

Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers.

2012-04-20

[Life Sci. 90(15-16) , 607-11, (2012)]

More Articles...